pI: 8.2164 |
Length (AA): 231 |
MW (Da): 26120 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
17 | 65 | 5evj (A) | 150 | 201 | 16.00 | 0.00096 | 0.17 | 0.284221 | 0.36 |
21 | 58 | 2gs9 (A) | 88 | 128 | 32.00 | 0.0035 | 0.49 | 0.402602 | 0.52 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_128282)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G18400 | anamorsin homolog |
Babesia bovis | BBOV_I003760 | hypothetical protein |
Brugia malayi | Bm1_48140 | Hypothetical 25.6 kDa protein T20B12.7 in chromosome III |
Candida albicans | CaO19.2825 | contains a match to DUF689 |
Candida albicans | CaO19.10342 | contains a match to DUF689 |
Candida albicans | CaO19.10343 | similar to N terminus of S. cerevisiae YKR071C |
Caenorhabditis elegans | CELE_T20B12.7 | Protein T20B12.7 |
Cryptosporidium hominis | Chro.60473 | hypothetical protein |
Cryptosporidium parvum | cgd6_4130 | conserved hypothetical protein |
Dictyostelium discoideum | DDB_G0285251 | hypothetical protein |
Drosophila melanogaster | Dmel_CG4180 | CIAPIN1 ortholog |
Echinococcus granulosus | EgrG_000621600 | Anamorsin |
Echinococcus multilocularis | EmuJ_000621600 | Anamorsin |
Homo sapiens | ENSG00000005194 | cytokine induced apoptosis inhibitor 1 |
Leishmania braziliensis | LbrM.07.0230 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_070390.1 | Cytokine-induced anti-apoptosis inhibitor 1, Fe-S biogenesis, putative |
Leishmania infantum | LinJ.07.0390 | hypothetical protein, conserved |
Leishmania major | LmjF.07.0230 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.07.0230 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_08430 | hypothetical protein |
Mus musculus | ENSMUSG00000031781 | cytokine induced apoptosis inhibitor 1 |
Neospora caninum | NCLIV_059410 | hypothetical protein |
Oryza sativa | 4337380 | Os04g0674400 |
Oryza sativa | 9266719 | Os04g0682050 |
Onchocerca volvulus | OVOC1117 | Anamorsin homolog |
Plasmodium berghei | PBANKA_0706000 | Fe-S cluster assembly protein DRE2, putative |
Plasmodium falciparum | PF3D7_0824600 | Fe-S cluster assembly protein DRE2, putative |
Plasmodium knowlesi | PKNH_1318600 | Fe-S cluster assembly protein DRE2, putative |
Plasmodium vivax | PVX_089130 | Fe-S cluster assembly protein DRE2, putative |
Plasmodium yoelii | PY03124 | hypothetical protein |
Saccharomyces cerevisiae | YKR071C | Dre2p |
Schistosoma japonicum | Sjp_0091310 | IPR000005,Helix-turn-helix, AraC type,domain-containing |
Schistosoma japonicum | Sjp_0069250 | Anamorsin, putative |
Schistosoma mansoni | Smp_146230 | hypothetical protein |
Schistosoma mansoni | Smp_006210 | hypothetical protein |
Schmidtea mediterranea | mk4.003915.00 | Anamorsin homolog |
Trypanosoma brucei gambiense | Tbg972.8.1370 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.8.1750 | Fe-S cluster assembly protein DRE2 |
Trypanosoma congolense | TcIL3000_8_1660 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.511393.79 | Cytokine-induced anti-apoptosis inhibitor 1, Fe-S biogenesis, putative |
Trypanosoma cruzi | TcCLB.505071.119 | Cytokine-induced anti-apoptosis inhibitor 1, Fe-S biogenesis, putative |
Toxoplasma gondii | TGME49_216900 | cytokine induced apoptosis inhibitor 1 family protein |
Theileria parva | TP01_0461 | hypothetical protein, conserved |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.1750 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.1750 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.1750 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.1750 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_T20B12.7 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_T20B12.7 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_T20B12.7 | Caenorhabditis elegans | slow growth | wormbase |
YKR071C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0706000 | Plasmodium berghei | Essential | plasmo |
TGME49_216900 | Toxoplasma gondii | Probably essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.